Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) (State or other juris ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Daniel Reuvers - President & Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Simran Kaur - Piper Sandler Margaret Kaczor - William Blair & Company Suraj Kalia - Oppenheimer & Co. Inc. Operator Welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2023 Earnings Conference Call for Tactile Medical. [Operator Instructions] ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) Delaware 3701 Wayzata Blvd ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Daniel Reuvers - President and Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Simran Kaur - Piper Sandler Margaret Kaczor - William Blair & Company Ryan Zimmerman - BTIG Suraj Kalia - Oppenheimer & Co. Inc. Operator Welcome, ladies and gentlemen, to the First Quarter of Fiscal Year 2023 Earnings Conference Call for Tactile Medical. At t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) Delaware 3701 Wayzata Blv ...

Financial Data and Key Metrics - Total revenue increased 20% year-over-year to $73.9 million in Q4 2022, exceeding the high end of the updated fiscal year guidance range [13] - Lymphedema product revenue grew 14% year-over-year to $65.8 million, while airway clearance product revenue surged 90% year-over-year to $8.1 million [6][42] - GAAP net income was $4.6 million ($0.23 per diluted share), compared to a net loss of $7.5 million in the prior year period [46] - Adjusted EBITDA increased 27% year-over-year to $12.1 million, representing 16% of sales [46] - Free cash flow generated was $3.8 million, helping fund a $5 million milestone payment related to the AffloVest acquisition [15] Business Line Performance - Lymphedema product line returned to double-digit revenue growth in Q4 2022, driven by improved sales team productivity and stabilization of clinic throughput [7][22] - Airway clearance product line achieved 109% annual growth in 2022 following the AffloVest acquisition, with strong demand from DME distributors [22][21] - ComfortEase lower extremity garments and Kylee Mobile Application launched in July 2022, contributing to strong sales of lymphedema systems for lower extremities [17][27] Market and Channel Performance - Revenue by channel: $41.4 million from commercial payers, $18 million from Medicare, $8.1 million from DME distributors, and $6.4 million from the VA [43] - VA centers showed anecdotal signs of resuming patient visits, though not yet a broad trend [66] - CMS discontinued the policy requiring certificates of medical necessity for pneumatic compression device claims, providing an opportunity for increased engagement with prescribers [34] Strategic Priorities and Industry Competition - Key strategic priorities for 2023 include improving lymphedema sales team productivity, deepening relationships with DME providers, introducing new products, and enhancing operational efficiency [30] - The company aims to deliver at least $350 million in total revenue and $50 million of adjusted EBITDA by 2025, with a focus on underserved chronic conditions [54][69] - New product innovations, such as Bluetooth-enabled Flexitouch Plus and Kylee app updates, aim to enhance patient experience and compliance [8][102] Management Commentary on Operating Environment and Future Outlook - Management expressed cautious optimism for 2023, citing potential tailwinds from sales productivity expansion, new product traction, and payer policy improvements [32] - Supply chain constraints for AffloVest are expected to ease in 2023, with production capacity expanded through a second supplier [16][74] - Macroeconomic uncertainties, such as potential recession impacts on consumer spending and co-pays, were factored into the 2023 guidance [55][80] Other Important Information - The company hosted 43 educational programs in Q4 2022, attended by approximately 1,300 clinicians, and trained nearly 6,500 participants throughout the year [28] - A continuing education unit course on obesity-related lymphedema was launched in December 2022, drawing 266 attendees [28] - CFO Brent Moen announced his intention to retire in 2023, with a successor search underway [40][41] Q&A Session Summary Question: 2023 Revenue Guidance and Assumptions - 2023 revenue guidance assumes 9%-11% growth, with lymphedema products growing 8%-9% and airway clearance products growing 18%-22% [47][72] - Supply chain headwinds for AffloVest are expected to diminish, with no significant revenue contribution from new product launches factored into the guidance [72][74] Question: Sales Team Productivity and Headcount - The company ended 2022 with 250 sales representatives, consistent with Q4 headcount, and expects to maintain this level through at least the first half of 2023 [15][75] - Sales productivity improved in Q4, with the team engaging previously unrepresented accounts and benefiting from reduced turnover compared to 2021 [7][113] Question: VA Center Reopening Impact - Anecdotal evidence suggests some VA centers have resumed patient visits, but the impact on 2023 results remains uncertain [66][73] Question: Adjusted EBITDA and Free Cash Flow Expectations - Adjusted EBITDA is expected to grow over 30% in 2023, driven by improved cost management and reduced legal expenses [57][110] - Free cash flow generation is anticipated to support growth investments, with a cumulative $75 million expected from 2023 to 2025 [69][108] Question: New Product Pipeline - The company plans to introduce a size extension for AffloVest in H1 2023, refresh the Entree device, and launch upper extremity ComfortEase garments in H2 2023 [100][112] - Kylee app updates will include measurement tracking, reminders, and encouragement prompts to enhance patient compliance and reduce cost to serve [102][114]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37799 Tactile Systems Technology, Inc. (Exact name of registrant as specified in its charter) 3701 Wayzata Blvd, S ...

Tactile. MEDICAL® Investor Presentation November 2022 NASDAQ: TCMD Forward-Looking Statements Disclosure This presentation contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," "continue," "confident," "outlook," "guidance," "project," "goals," "look forward," "poised," "designed," "plan," "return," "focused," "positioned," "prospects," or "remain" or the n ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Dan Reuvers - President and Chief Executive Officer Brent Moen - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Margaret Kaczor - William Blair Suraj Kalia - Oppenheimer Operator Welcome, ladies and gentlemen to the Third Quarter of Fiscal Year 2022 Earnings Conference Call for Tactile Medical. [Operator Instructions] At the end of the company’s prepare ...

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Company Participants Dan Reuvers - President and CEO Brent Moen - CFO Conference Call Participants Ryan Zimmerman - BTIG Simran Kaur - Piper Sandler Margaret Kaczor - William Blair Suraj Kalia - Oppenheimer & Company Operator Welcome ladies and gentlemen to the Second Quarter of Fiscal Year 2022 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-o ...